Swiss M&A Report: market and valuation update for the Health Industries sector

As well as an overview of the general transaction environment in the Swiss Health Industries sector, the publication delivers comprehensive insights into the past and current valuation levels of eight sub-sectors (Big Pharma, Biotech, CRO/CDMO, Diagnostic Services, Elderly and Specialist Care, Generics, Hospitals and MedTech) covering the entire Swiss Health Industries market, as well as sector-specific growth rates and margins.

Current M&A environment in the Health Industries sector

June 2024

The Swiss Health Industries market experienced a consistently high volume of deals in 2023 and throughout the first quarter of 2024. This robust deal activity can be attributed to the strong participation of financial sponsors and the notable presence of cross-border transactions within the sector, highlighting the international importance of the Swiss Health Industries market. Despite the challenging M&A market across various industries, the Health Industries sector remains attractive for both buyers and sellers due to its anti-cyclical nature. Swiss health companies, being at the forefront of industry trends, are expected to prioritise optimising their capabilities and pursuing inorganic growth opportunities.